SEC Form 4 · accession 0001104659-15-074204

Dimension Therapeutics, Inc. · DMTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 27, 2015

Accepted (ET)

Oct 29, 2015 · 6:14 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001592288

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Oct 27, 2015	C	1,097,745	—	A	1,097,745	I	See Footnote
Common Stock^F2	Oct 27, 2015	P	961,538	$13.00	A	2,059,283	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series B Preferred Stock^F1,F2	—	Oct 27, 2015	C	3,208,711	D	—	—	Common Stock	1,097,745	0	I

F1The Series B Preferred Stock automatically converted into Common Stock, for no additional consideration, on a 2.923-for-1 basis at the closing of the Issuer's initial public offering, and had no expiration date.
F2These securities are held by New Leaf Ventures III, L.P. ("NLV-III") and New Leaf Growth Fund I, L.P. ("NLGF"). New Leaf Venture Associates III, L.P. ("NLVA-III") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III") is the general partner of NLVA-III. New Leaf Growth Associates I, L.P. ("NLGA") is the general partner of NLGF and NLVM-III is the general partner of NLGA. Reporting Person is employed by New Leaf Venture Partners, L.L.C., which is affiliated with the above entities and disclaims beneficial ownership of the shares held by NLV-III and NLGF except to the extent of his pecuniary interests therein if any.